Thrombolytic therapy for acute myocardial infarction in the elderly

Coronary Artery Disease

Volumn 11, Issue 4, 2000, Pages 299-304

  Straznicky, Ivan T ^a   White, Harvey D ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

Elderly; Myocardial infarction; Reperfusion; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; AGED; ATRIOVENTRICULAR BLOCK; BLEEDING; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELDERLY CARE; FIBRINOLYTIC THERAPY; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; REVIEW;

AGED; COST-BENEFIT ANALYSIS; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0034125731     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200006000-00002     Document Type: Review

References (26)

1. 1 Paul DS, O'Gara PT, Mahjoub ZA, DiSalvo TG, O'Donnell CJ, Newell JB, et al. Geriatric patients with acute myocardial infarction: cardiac risk factor profiles, presentation, thrombolysis, coronary interventions and prognosis. Am Heart J 1996; 131:710-715.
2. 2 Gurwitz JH, Goldberg RJ, Gore JM. Coronary thrombolysis for the elderly? JAMA 1991; 265:1720-1723.
3. 3 Roig E, Castaner A, Simmons B, Patel R, Ford E, Cooper R. In-hospital mortality rates from acute myocardial infarction by race in US hospitals: findings from the national hospital discharge survey. Circulation 1987; 76:280-288.
4. 4 Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, et al. The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. JAMA 1997; 277:535-542.
5. 5 Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343:311-322. A meta-analysis of all major clinical trials comparing thrombolytic therapy with placebo therapy for acute myocardial infarction.
6. 6 White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver D, et al. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial. Circulation 1996; 94:1826-1833. The nett clinical benefits of four alternative thrombolytic and antithrombotic regimens for treating acute infarction in patients in various age groups are presented.
7. 7 Lee KL, Woodlief LH, Topol EJ, Weaver WD, Bertriu AB, Col J, et al. for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41021 patients. Circulation 1995; 91:1659-1668.
8. 8 Lesnefsky EJ, Lundergan CF, Hodgson JM, Nair R, Reiner JS, Greenhouse SW, et al. Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience. J Am Coll Cardiol 1996; 28:331-337.
9. 9 Weaver WD, Litwin PE, Martin JS, Kudenchuk PJ, Maynard C, Eisenberg MS, et al. for the MITI Project Group. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991; 18:657-662.
10. 10 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329:1615-1622.
11. 11 French J, Williams W, Hart H, Woo K, Wang L, Grant J, et al. Management of acute myocardial infarction in Auckland. NZ Med J 1996; 109:248-251.
12. 12 Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; i:397-402.
13. 13 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii:349-360.
14. 14 Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R, on behalf of the ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ISIS-2: 10 year survival in a randomised comparison of intravenous streptokinase, oral aspirin, both, or neither among patients with suspected acute myocardial infarction. BMJ 1998; 316:1337-1343.
15. 15 Straznicky IT, White HD. Thrombolysis in elderly patients. In: Califf RM (editor): Thrombolytic therapy: new standards for AMI care: part IV: patients with complicating cardiac conditions. Belle Mead, NJ: American Journal of Cardiology; 1998. pp. 23-28.
16. 16 Daida H, Kottke TE, Backes RJ, Gersh BJ, Tangalos EG, Baile KR. Are coronary-care unit changes in therapy associated with improved survival of elderly patients with acute myocardial infarction? Mayo Clin Proc 1997; 72:1014-1021.
17. 17 Gottleib S, Goldbourt U, Boyko V, Barbash G, Mandelzweig L, Reicher-Reiss H, et al. Improved outcome of elderly patients (≥ 75 years of age) with acute myocardial infarction from 1981-1983 to 1992-1994 in Israel. Circulation 1997; 95:342-350.
18. 18 Stevenson R, Ranjadayalan K, Wilkinson P, Roberts R, Timmis AD. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. BMJ 1993; 307:349-353.
19. 19 Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I trial. Circulation 1995; 92:2811-2818. These authors confirmed the importance of age as a risk factor for haemorrhagic strokes after thrombolytic therapy.
20. 20 Krumholz HM, Pasternak RC, Weinstein MC, Freisinger GC, Ridker PM, Tostesom AN, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992; 327:7-13.
21. 21 Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332:1418-1424.
22. 22 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337:1118-1123.
23. 23 The Continuous Infusion Versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double bolus administration for acute myocardial infarction. N Engl J Med 1997; 337:1124-1130.
24. 24 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335:775-782.
25. 25 Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 Double-Blind Randomised Trial. Lancet 1999; 354:716-722.
26. 26 Barron HV, Fox NL, Berioloi S, Danays T, Li X, Wang-Clow F, Van de Werf F. A comparison of intracranial hemorrhage rates in patients treated with rtPA and tPA-TNK: Impact of gender, age and low body weight [abstract]. Circulation 1999; 100 (suppl 1):1-1.